BRAF and thyroid cancer: Thus, evaluation of the effects of HIF-1α inhibition in the mutant BRAF thyroid cancer cell line (BCPAP) would have a significant clinical implication in terms of the high BRAF mutation prevalence in thyroid cancer and its association with poor outcomes.